Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06974097

Acronym

NEO-TAN

Enrollment

Registered

2025-05-15

Start date

2025-07-01

Completion date

2028-12-30

Last updated

2025-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Brief summary

evaluate the predictive value of circulating neutrophil DNA methylation profiles, identified from the ALCINA 2 cohort, on pre-treatment blood samples (T0), for the histological response to neoadjuvant chemo-immunotherapy in patients with resectable non-small cell lung cancer (NSCLC)

Interventions

OTHERblood sampling

blood sampling

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years. * Resectable non-small cell lung cancer (NSCLC), stage IIA to IIIB. * Lymph node status obtained by Positron Emission Tomoscintigraphy (PET)-scanner, confirmation of lymph node status by optional histological sampling (mediastinoscopy, thoracoscopy, echo-endoscopy). * No secondary lesions in the cerebrum or extra-cerebrum confirmed on brain MRI, PET scanner +/- injected cerebro-thoraco-abdomino-pelvic scanner. * Neoadjuvant immunochemotherapy strategy validated by a multidisciplinary consultation meeting (RCP) prior to the start of treatment. * Lung function compatible with thoracic surgery, patient meets surgical and anesthetic criteria for operability * Measurable disease according to RECIST criteria version 1.1

Exclusion criteria

* Previous systemic treatment for the same CBNPC. * Diagnosis of another solid tumor within the last 3 years, ‡ excluding non melanoma cutaneous and cervical carcinomas . * Contraindication to immunotherapy. * Non-objection to participate in research not collected. * Patients unable to read and/or write. * Inability to monitor patient during study period * Persons unable to express their consent. * Not affiliated to a social security scheme. * Persons under court protection. * Persons participating in another research study with an ongoing exclusion period. * Pregnant women

Design outcomes

Primary

Measure	Time frame
Area under the ROC curve (AUC) of neutrophil DNA methylation profiles for predicting histologic response	6 Months after inclusion

Countries

France

Contacts

Primary ContactCamille TRAVERT, Principal Investigator

camille.travert@chu-montpellier.fr033 4 67 33 61 35

Backup ContactAnne CADENE

a-cadene@chu-montpellier.fr0 33 4 67 33 08 14

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026